Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

11-052018

Bio-Thera Solutions Announces Initiation of Pivotal Phase III Study of BAT8001 for Patients with Metastatic Breast Cancer

Guangzhou, China -- Bio-Thera Solutions, announced the initiation of a Phase III clinical trial evaluating the efficacy...
08-242018

Bio-Thera Solutions Announces China National Drug Administration Acceptance of Biologics License Application for Proposed Biosimilar to Humira® (Adalimumab)

Bio-Thera Solutions, a global biopharmaceutical company today announced that the China National Drug Administration (CND...
07-262018

Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT-1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

July 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina ...

上一页 ···30 31 32 33 34 ··· 下一页